Trial Profile
A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs N acetyl D mannosamine (Primary)
- Indications Nonaka distal myopathy
- Focus Adverse reactions
- 24 Apr 2021 Results of Pop PK analysis and plasma ManNAc and Neu5Ac pharmacokinetic data were obtained from two clinical studies: NCT01634750, NCT02346461 published in the Drugs in R and D
- 26 Aug 2015 New trial record